Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ecopia Down the garden path

Despite the breakthrough nature of past successes in microbial discovery, relatively few small molecule discovery companies are reexamining the old ground of chemical compounds derived from microbial sources.

Ecopia BioSciences Inc. believes that by applying the tools of genomics and high throughput screening to comb through microbial genomes for the genetic basis of such molecules, the company has a high probability not only of identifying bioactive drug candidates, but of discovering sets of genetic and enzymatic tools that will

Read the full 792 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE